Mira Dx
Mira Dx, Inc.: LA-based developer and manufacturer of genetic testing kits for ovarian cancer risk.
Founded
2008Mira Dx, Inc.: LA-based developer and manufacturer of genetic testing kits for ovarian cancer risk.
Mira Dx, Inc., founded in Los Angeles, focuses on developing and manufacturing advanced genetic testing kits. The company's core mission is to leverage unique microRNA-based biomarkers to personalize cancer treatments and drug development. Their primary products include genetic tests that identify patients with an increased risk of developing ovarian cancer and the PROSTOX™ Test, a radiogenomics assay designed to help prostate cancer patients avoid radiation toxicity. Mira Dx partners with cancer clinics and pharmaceutical companies to enhance personalized cancer care.
Notable affiliates and investors in Mira Dx include leading oncologists and biotech investors committed to advancing precision medicine. Key achievements of the company include the successful development and deployment of the PROSTOX™ Test, which has significantly impacted the management of prostate cancer treatment by reducing radiation-related side effects. Mira Dx's innovative approach to using microRNA biomarkers has positioned it as a pivotal player in the personalized oncology market, enhancing patient outcomes and contributing to the evolution of targeted cancer therapies.
Companies similar to Mira Dx include Mira Oncology, Mirvie, Milagen and Arphion.
Mira Dx was founded in 2008.
Mira Dx's headquarters is located in New Haven, CT, US.
Mira Dx's most recent funding round was for $4M (USD) in July 2010.
As of Jul 1, 2010, Mira Dx has disclosed funding of $4M (USD). Undisclosed round amounts are excluded.
Mira Dx has 30 employees as of Feb 4, 2024.
Arphion
